Providence Swedish Inflammatory Bowel Disease Conference 2025

Advanced IBD Management, Precision Medicine & Emerging Therapies Update

The Providence Swedish Inflammatory Bowel Disease Conference 2025 delivers a comprehensive update on the rapidly evolving field of inflammatory bowel disease (IBD), focusing on the integration of precision medicine, artificial intelligence, advanced therapeutics, nutritional strategies, and multidisciplinary care. Designed for clinicians managing complex cases of Crohn’s disease and ulcerative colitis, this conference provides practical, evidence-based approaches to improving long-term patient outcomes.

Through expert-led presentations and case-based discussions, participants gain insight into modern treatment paradigms, including treat-to-target monitoring, therapy de-escalation, IL-23 inhibitor positioning, acute severe ulcerative colitis management, nutritional interventions, pain management, and surgical decision-making.

The program also highlights emerging technologies and the future role of AI in personalized IBD care, reflecting the next generation of gastroenterology practice.

Product Details

• Format: 17 Videos (.MP4) + 13 Audios (.MP3) + 13 Subtitle Files (.VTT)
• Total Size: 8.75 GB
• Course Year: 2025
• Access: On-Demand
• Level: Intermediate to Advanced

Program Overview

Inflammatory bowel disease management continues to advance with new biologic therapies, precision medicine approaches, advanced monitoring techniques, and growing use of digital health tools.

This conference provides updates on:

• Crohn’s disease
• Ulcerative colitis
• Precision medicine
• Artificial intelligence in gastroenterology
• Treat-to-target strategies
• Therapy de-escalation
• IL-23 inhibitors
• Nutritional therapy
• Pain management
• Opioid reduction
• Acute severe ulcerative colitis
• Surgical management of IBD
• Intra-abdominal abscesses
• DDW 2025 clinical updates

The curriculum focuses on practical implementation of emerging evidence into everyday IBD practice.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Evaluate the role of precision medicine in inflammatory bowel disease management.
• Assess current and future applications of artificial intelligence in IBD care.
• Implement treat-to-target monitoring strategies.
• Develop safe and effective treatment de-escalation plans.
• Utilize nutritional therapies in Crohn’s disease and ulcerative colitis.
• Manage pain while minimizing opioid exposure.
• Apply updated therapeutic positioning for ulcerative colitis treatments.
• Recognize indications for surgical intervention in IBD.
• Manage intra-abdominal abscesses and other Crohn’s disease complications.
• Integrate key clinical updates presented at DDW 2025.

Core Topics Covered

Precision Medicine in IBD

A major focus of the conference is the movement toward individualized treatment strategies.

Topics include:

• Personalized therapy selection
• Biomarker-guided treatment
• Disease phenotyping
• Risk stratification
• Predictive analytics
• Future directions in precision gastroenterology

Faculty discuss how precision medicine may transform long-term disease management.

Artificial Intelligence in Gastroenterology

The course explores emerging applications of AI including:

• Clinical decision support
• Disease monitoring
• Endoscopic assessment
• Predictive modeling
• Patient management optimization

Participants gain insight into how technology is reshaping IBD care.

Treat-to-Target Monitoring

Sessions review:

• Objective disease monitoring
• Endoscopic remission
• Biomarker utilization
• Therapeutic optimization
• Disease activity assessment

The conference emphasizes proactive management strategies designed to improve outcomes.

Treatment De-escalation

A dedicated section focuses on:

• Candidate selection
• Biologic de-escalation
• Safety considerations
• Relapse prevention
• Long-term disease control

Experts discuss balancing treatment effectiveness with medication burden and safety.

Ulcerative Colitis Updates

Faculty provide comprehensive reviews of:

• Moderate-to-severe ulcerative colitis
• Acute severe ulcerative colitis (ASUC)
• Advanced therapies
• Treatment sequencing
• IL-23 inhibitor positioning

Current evidence and guideline recommendations are examined in detail.

Crohn’s Disease Management

Topics include:

• Complicated Crohn’s disease
• Fistulizing disease
• Intra-abdominal abscesses
• Advanced biologics
• Surgical considerations
• Long-term monitoring

Case-based discussions highlight practical management approaches.

IL-23 Inhibitors & Emerging Therapies

The conference reviews:

• IL-23 pathway biology
• New biologic therapies
• Clinical trial updates
• Comparative efficacy
• Safety profiles
• Treatment positioning

Participants gain updates on one of the fastest-growing therapeutic areas in IBD.

Nutrition in IBD

Nutritional management sessions address:

• Dietary interventions
• Exclusive enteral nutrition
• Nutritional optimization
• Micronutrient deficiencies
• Diet-based symptom control

Faculty discuss evidence supporting nutritional strategies in both Crohn’s disease and ulcerative colitis.

Pain Management & Opioid Reduction

Topics include:

• Chronic abdominal pain
• Non-opioid pain strategies
• Multidisciplinary management
• Opioid de-escalation
• Quality-of-life improvement

The program emphasizes safer, patient-centered approaches to symptom management.

Surgical Management of IBD

The conference explores:

• Surgical indications
• Ulcerative colitis surgery
• Crohn’s disease complications
• Postoperative management
• Multidisciplinary surgical care

Surgeons and gastroenterologists collaborate to review optimal timing and patient selection.

DDW 2025 Highlights

A special session reviews important developments from Digestive Disease Week (DDW) 2025, including:

• Clinical trial updates
• Emerging therapies
• New treatment algorithms
• Future directions in IBD research

Participants receive concise summaries of the most impactful studies influencing current practice.

Educational Features

✔ Comprehensive Crohn’s Disease & Ulcerative Colitis Update

✔ Precision Medicine & Personalized Care

✔ Artificial Intelligence in IBD Practice

✔ Treat-to-Target Monitoring Strategies

✔ IL-23 Inhibitor Updates

✔ Nutritional Therapy Education

✔ Surgical Management Discussions

✔ DDW 2025 Clinical Highlights

Target Audience

This course is ideal for:

• Gastroenterologists
• Colorectal Surgeons
• IBD Specialists
• Hepatogastroenterologists
• Internal Medicine Physicians
• Advanced Practice Providers
• Gastroenterology Fellows
• Surgical Fellows
• Multidisciplinary IBD Teams

Why This Course Stands Out

✔ Strong focus on precision medicine and AI integration

✔ Comprehensive review of emerging IBD therapies

✔ Practical guidance on treatment de-escalation

✔ Advanced discussions on IL-23 inhibitors

✔ Multidisciplinary gastroenterology and surgical perspectives

✔ Evidence-based nutritional management strategies

✔ Coverage of acute severe ulcerative colitis

✔ Incorporates latest DDW 2025 clinical updates

Clinical & Educational Value

The Providence Swedish Inflammatory Bowel Disease Conference 2025 provides a modern, forward-looking review of inflammatory bowel disease management. By integrating advances in biologic therapy, precision medicine, artificial intelligence, nutrition, surgery, and disease monitoring, the program equips clinicians with practical tools to optimize care for patients with Crohn’s disease and ulcerative colitis.

4. Topics

1. The Future of IBD Care – How Close are We to Precision Medicine (2025 Update)

2. If it Ain’t Broke, Don’t Fix It – Treatment De-Escalation in IBD

3. Monitoring Patients on IBD Therapy and Treat-to-Target

4. Nutritional Therapy and Pain Management in IBD

5. Q&A – Getting Patient Buy-in for Opiate De-escalation, Leniency with Medication Adherence in Patients with Moderate UC

6. The Role of Surgery in Ulcerative Colitis Care

7. Are All IL-23 Inhibitors the Same

8. Management of Acute Severe UC

9. The Management of Intra-Abdominal Abscesses in Crohn’s Disease

10. Will AI Put Us Out of (IBD) Business

11. Positioning Therapies for UC in 2025

12. Have We Made Progress in the Management of Cholestatic Liver Disease

13. IBD Updates from DDW 2025